GLMD
Income statement / Annual
Last year (2025), Galmed Pharmaceuticals Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Galmed Pharmaceuticals Ltd's net income was -$10.31 M.
See Galmed Pharmaceuticals Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.04 M |
$1.09 M |
$467.00 K |
| Cost of Revenue |
$0.00
|
$83.00 K
|
$31.00 K
|
$35.00 K
|
$42.00 K
|
$39.00 K
|
$35.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$83.00 K
|
-$31.00 K
|
-$35.00 K
|
-$42.00 K
|
-$39.00 K
|
-$35.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$4.87 M
|
$2.98 M
|
$3.57 M
|
$13.00 M
|
$27.22 M
|
$26.08 M
|
$18.18 M
|
$8.31 M
|
$9.65 M
|
$14.27 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.64 M
|
$3.22 M
|
$3.89 M
|
$4.62 M
|
$5.62 M
|
$4.09 M
|
$4.16 M
|
$4.05 M
|
$3.56 M
|
$2.91 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$8.51 M
|
$6.20 M
|
$7.46 M
|
$17.62 M
|
$32.84 M
|
$30.17 M
|
$22.34 M
|
$12.37 M
|
$13.21 M
|
$17.18 M
|
| Cost And Expenses |
$8.51 M
|
$6.28 M
|
$7.49 M
|
$17.65 M
|
$32.88 M
|
$30.21 M
|
$22.38 M
|
$12.75 M
|
$13.45 M
|
$17.35 M
|
| Interest Income |
$914.00 K
|
$503.00 K
|
$375.00 K
|
$297.00 K
|
$562.00 K
|
$1.19 M
|
$1.92 M
|
$959.00 K
|
$65.00 K
|
$35.00 K
|
| Interest Expense |
$0.00
|
$15.00 K
|
$11.00 K
|
$215.00 K
|
$43.00 K
|
$31.00 K
|
$33.00 K
|
$42.00 K
|
$49.00 K
|
$67.00 K
|
| Depreciation & Amortization |
$0.00
|
$83.00 K
|
$31.00 K
|
$35.00 K
|
$42.00 K
|
$39.00 K
|
$35.00 K
|
$387.00 K
|
$239.00 K
|
$169.00 K
|
| EBITDA |
-$8.51 M |
-$6.20 M |
-$7.46 M |
-$17.62 M |
-$32.84 M |
-$30.17 M |
-$22.34 M |
-$10.33 M |
-$12.13 M |
-$16.71 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-5.07
|
-11.18
|
-35.79
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-5.26
|
-11.4
|
-36.15
|
| Total Other Income/Expenses Net |
-$1.80 M
|
-$1.24 M
|
$580.00 K
|
-$215.00 K
|
$414.00 K
|
$1.44 M
|
$1.92 M
|
$934.00 K
|
$65.00 K
|
$35.00 K
|
| Income Before Tax |
-$10.31 M
|
-$7.52 M
|
-$6.91 M
|
-$17.87 M
|
-$32.47 M
|
-$28.77 M
|
-$20.46 M
|
-$9.78 M
|
-$12.30 M
|
-$16.85 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-4.8
|
-11.34
|
-36.07
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$75.00 K
|
$0.00
|
$106.00 K
|
| Net Income |
-$10.31 M
|
-$7.52 M
|
-$6.91 M
|
-$17.87 M
|
-$32.47 M
|
-$28.77 M
|
-$20.46 M
|
-$9.86 M
|
-$12.30 M
|
-$16.95 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-4.84
|
-11.34
|
-36.3
|
| EPS |
-2.39 |
-8.08 |
-30.05 |
-11.08 |
-19.48 |
-19.46 |
-13.17 |
-8.15 |
-14.77 |
-22.36 |
| EPS Diluted |
-2.39 |
-8.08 |
-29.95 |
-11.08 |
-19.48 |
-19.46 |
-13.17 |
-8.15 |
-14.77 |
-22.36 |
| Weighted Average Shares Out |
$4.31 M
|
$930.82 K
|
$230.00 K
|
$1.68 M
|
$1.64 M
|
$1.42 M
|
$1.41 M
|
$1.21 M
|
$832.49 K
|
$758.31 K
|
| Weighted Average Shares Out Diluted |
$4.31 M
|
$930.82 K
|
$230.79 K
|
$1.68 M
|
$1.64 M
|
$1.42 M
|
$1.41 M
|
$1.21 M
|
$832.49 K
|
$758.31 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
